ストックスクリーナーアプリを入手
2.99
10.33%
0.28
アフターアワーズ：
2.99
前日終値:
$2.71
開ける：
$2.89
24時間の取引高:
6.11M
Relative Volume:
0.70
時価総額：
$2.64B
収益：
$1.31M
当期純損益:
$-597.65M
株価収益率:
-3.0825
EPS:
-0.97
ネットキャッシュフロー:
$-425.62M
1週間 パフォーマンス:
+8.73%
1か月 パフォーマンス:
+8.33%
6か月 パフォーマンス:
-4.17%
1年 パフォーマンス:
-47.08%
1日の値動き範囲:
$2.87
$3.01
1週間の範囲:
$2.64
$3.01
52週間の値動き範囲:
$1.83
$7.48
Immunitybio Inc Stock (IBRX) Company Profile
IBRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.99 | 2.39B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-20 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | BTIG Research | Buy |
| 2023-05-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 開始されました | Jefferies | Buy |
Immunitybio Inc (IBRX) 最新ニュース
What analysts say about ImmunityBio Inc. stockHigh-yield market plays - Autocar Professional
ImmunityBio’s (IBRX) ANKTIVA Gets Approved by UK’s Medicines and Healthcare Regulatory Agency - Yahoo Finance
What drives ImmunityBio Inc. stock priceConsistently high yield - jammulinksnews.com
Is ImmunityBio Inc. a good long term investmentGame-changing returns - jammulinksnews.com
LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper - Benzinga
ImmunityBio: A High-Conviction Play on ANKTIVA's Expanding Indication and Immune-Boosting Platform - AInvest
ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval - Seeking Alpha
ImmunityBio Inc. Stock Analysis and ForecastSkyrocketing returns - jammulinksnews.com
ImmunityBio’s Anktiva Rollercoaster: From FDA Rejection and 55% Stock Drop to Approval - TradingView
ImmunityBio Settled With Investors Over FDA Rejection Drama— How to Claim Your Share - TradingView
ImmunityBio: High Stakes On ANKTIVA's Growth Amidst FDA Friction And Financial Pressures - Seeking Alpha
ImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study Update - TipRanks
Bullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA Authorization - MSN
ImmunityBio Stock Surges Amid Promising Trial Updates - TipRanks
ImmunityBio’s Innovative Approach to Bladder Cancer Treatment: A Clinical Study Update - TipRanks
ImmunityBio Granted UK Approval for Bladder Cancer Treatment - MarketScreener
ImmunityBio: D. Boral Capital Maintains Buy, Raises PT to $30 from $30 - AInvest
Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN
UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Lelezard
ImmunityBio's ANKTIVA® Secures UK Approval: A Catalyst for Global Oncology Leadership - AInvest
Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire
ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView
13 Stocks Under $5 With High Upside Potential - Insider Monkey
UK Regulator OKs ImmunityBio's Bladder Cancer Treatment for New Indication - MarketScreener
ImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer Trial Success - Insider Monkey
ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA - Yahoo Finance
Anktiva Approved For Additional Treatment - Los Angeles Business Journal
ImmunityBio Approves 2025 Equity Incentive Plan - TipRanks
ImmunityBio's $10.5M Investor Deal Gets Final OK - Law360
ImmunityBio Gets Final OK for $10.5 Million Investor Settlement - Bloomberg Law News
ImmunityBio’s ANKTIVA & FDA Expanded Access: Transforming bladder cancer treatment - pharmaphorum
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry - newswire.ca
ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion - MSN
15 Stocks That Stole The Show Last Week - Insider Monkey
Deadline to Claim Your Payout from the $10.5M ImmunityBio Settlement Is in 1 Month - TradingView
Why ImmunityBio, Inc. (IBRX) Skyrocketed Today - Yahoo Finance
H.C. Wainwright maintains buy rating on ImmunityBio stock after FDA milestones - Investing.com Nigeria
ImmunityBio (IBRX) Receives Reiterated Buy Rating from HC Wainwr - GuruFocus
Immunitybio Inc (IBRX) 財務データ
収益
当期純利益
現金流量
EPS
4.91%
0.25%
大文字化:
|
ボリューム (24 時間):